+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06820463

Evaluating Safety and Effectiveness of Telisotuzumab Adizutecan Combined With Chemotherapy and Targeted Therapy in Adults With Metastatic Colorectal Cancer

Led by AbbVie · Updated on 2026-10-27

390

Participants Needed

82

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Metastatic colorectal cancer mCRC is the focus of this study, which evaluates the safety and disease activity changes when telisotuzumab adizutecan is combined with oxaliplatin, fluorouracil 5FU, leucovorin LV, bevacizumab, or panitumumab. This phase 2 trial aims to assess adverse events and efficacy of these combinations in adults with mCRC, addressing an important cancer type with high incidence, especially in developed countries. The study has two main parts a dose escalation phase and a dose optimization phase. In the dose escalation phase, participants receive increasing intravenous doses of telisotuzumab adizutecan alongside FOLFOX fluorouracil, leucovorin, oxaliplatin with bevacizumab or 5FULV with panitumumab until a tolerable and potentially effective dose is identified. In the dose optimization phase, participants are randomized to receive either one of two optimized doses of telisotuzumab adizutecan combined with FOLFOX and bevacizumab or 5FULV and panitumumab, or the comparator treatment of FOLFOX with bevacizumab or panitumumab. This study is planned to last about six years and will enroll approximately 390 adults worldwide. Participants will attend regular visits at approved hospitals or clinics for treatment and monitoring throughout the study. Researchers will perform frequent medical assessments including blood tests, questionnaires, and monitor side effects to evaluate treatment impact. The main outcomes studied include objective response rate complete or partial tumor response within 24 weeks and adverse events over approximately six years. Additional outcomes like progression-free survival, duration of response, overall survival, and disease control are also tracked to understand treatment effects and safety over time.

CONDITIONS

Brief Title

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here